Open AccessS875 The Evolution of Clinical Trial Design in Ulcerative Colitis: Interpreting Future Endpoints Based on Post-Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1
Author(s) -
William J. Sandborn,
Bruce E. Sands,
Sharif Uddin,
Karen Lasch,
Rana Qasim Khan
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000777032.10922.69
Subject(s) - vedolizumab , medicine , ulcerative colitis , clinical trial , clinical endpoint , post hoc analysis , placebo , inflammatory bowel disease , post hoc , phases of clinical research , surrogate endpoint , disease , surgery , pathology , alternative medicine